The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | The NEXT platform: drug sensitivity screening for AML
Raphael Itzykson, MD, PhD, Saint-Louis Hospital AP-HP, Paris, France, discusses the development of the niche-like ex vivo high throughput (NEXT) platform, a multiparametric drug sensitivity screening platform for primary acute myeloid leukemia (AML). The platform was validated in patients with NPM1 mutant AML treated with conventional daunorubicin plus cytarabine (DNR-AraC) chemotherapy. The results found that the NEXT assay could predict measurable residual disease (MRD) achievement in NPM1 mutant AML and identify novel sensitizers to DNA-AraC. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Raphael Itzykson, MD, PhD, has received research funding from Janssen, Novartis and Oncoethix (now Merck); has received honoraria from Sanofi, BMS and Celgene; and has done consultancy work with Novartis, Otsuka Pharma, Jazz Pharmaceuticals, Karyopharm and StemLine.
